Join to access to all OVN content. Join for Free
Product Safety and its Role in Medical Affairs
Medical Safety Product Safety MSLs Communication AI in Healthcare Regulatory Changes

Product Safety and its Role in Medical Affairs


Share This Article


Summary

This week's guest is Juan Daccach, MD, VP Global Product Safety at Merz Aesthetics who discusses Safety and its role in Medical/Product Safety and the interaction between safety physicians and medical affairs physicians (for both pharma and device)

Key Points

  • Understanding the nuances of medical and product safety is crucial for MSLs to effectively communicate with healthcare providers and ensure patient safety.
  • MSLs play a pivotal role in bridging the gap between field observations and internal safety teams by reporting adverse events and potential product issues promptly.
  • The evolving landscape of AI, machine learning, and combination products is reshaping the medical device and pharma industries, emphasizing the need for MSLs to stay informed about regulatory changes and technological advancements.

Click for Source
Medical Safety, Product Safety, MSLs Communication, AI in Healthcare, Regulatory Changes

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Press Release
Breaking Silos in Oncology Dr Ramin Farhood & Dr Kirk Shepard on Voices of Oncology
OVN Avatar Joe Pardavila sits down with Dr. Ramin Farhood and Dr. Kirk Shepard

Breaking Silos in Oncology Dr Ramin Farhood & Dr Kirk Shepard on Voices of Oncology

Podcast
The Struggle With KOL Access in Todays World
Partner Avatar MSL Talk: Tom Caravela, Carsten Schnatwinkel, Jeanna Cooper

The Struggle With KOL Access in Todays World

Podcast
The Future of MSL Roles: Skills and Competencies for Tomorrow’s Challenges
Partner Avatar MSL Talk: Tom Caravela, Stephanie Otis

The Future of MSL Roles: Skills and Competencies for Tomorrow’s Challenges

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Explore OVN